MicroPort CardioFlow Medtech Corp. (HK:2160)
:2160
Want to see HK:2160 full AI Analyst Report?
2160 Stock Chart & Stats
HK$1.25
HK$0.04(6.15%)
At close: 4:00 PM EST
HK$1.25
HK$0.04(6.15%)
Day’s Range― - ―
52-Week RangeHK$1.43 - HK$8.46
Previous CloseN/A
Volume546.00K
Average Volume (3M)8.07M
Market Cap
HK$1.91B
Enterprise ValueHK$450.53M
Total Cash (Recent Filing)HK$1.38B
Total Debt (Recent Filing)HK$258.36M
Price to Earnings (P/E)―
Beta1.90
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.49
Shares Outstanding1,273,311,400
10 Day Avg. Volume7,535,058
30 Day Avg. Volume8,069,439
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)1.49
Price to Sales (P/S)6.71
P/FCF Ratio-10.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.3
Revenue Forecast (FY)HK$2.18B
Bulls Say, Bears Say
Bulls Say
Steady Revenue GrowthConsistent top-line growth (8.7% YoY to 399.4M) indicates durable demand and expanding market penetration for cardiovascular devices. Over 2–6 months this trend supports scale benefits, improved bargaining leverage with customers, and a clearer path to fixed-cost absorption if maintained.
Solid Gross MarginsA roughly 55% gross margin signals strong product economics and pricing power in core device and consumable lines. This margin base can sustain R&D and go-to-market investment and provides a structural buffer against input cost inflation, aiding prospects for eventual operating leverage as sales scale.
Reduced Cash Burn Versus Prior YearsThe company reports materially smaller cash burn versus 2021–2024, reflecting improving operational control or revenue mix. A downward cash-burn trajectory is a durable positive: it lowers near-term financing need and increases runway, improving chances to reach self-sustaining operations if trends continue.
Bears Say
Sharp Leverage IncreaseLeverage spiked to roughly 1.62B and a debt-to-equity near 6.3x, a structural shift that raises refinancing and covenant risk. High leverage limits strategic flexibility, increases interest exposure, and magnifies downside if revenue or reimbursement pressures persist, making balance-sheet repair a medium-term priority.
Negative Free Cash FlowFCF remained meaningfully negative (~-38.3M) with slightly negative operating cash flow, indicating the business is not yet self-financing. Persistent FCF deficits force ongoing external funding or structural cost changes; this is a durable constraint on reinvestment and increases execution risk until reversed.
Persisting Operating LossesDespite revenue growth and solid gross margins, the company reported a wide net margin (~-33%), meaning scale hasn't converted to profitability. Ongoing losses erode equity returns, constrain reinvestment capacity, and increase the likelihood of dilutive financing or strategic restructuring if not corrected over the medium term.
MicroPort CardioFlow Medtech Corp. News
2160 FAQ
What was MicroPort CardioFlow Medtech Corp.’s price range in the past 12 months?
MicroPort CardioFlow Medtech Corp. lowest stock price was HK$1.43 and its highest was HK$8.46 in the past 12 months.
What is MicroPort CardioFlow Medtech Corp.’s market cap?
MicroPort CardioFlow Medtech Corp.’s market cap is HK$1.91B.
When is MicroPort CardioFlow Medtech Corp.’s upcoming earnings report date?
MicroPort CardioFlow Medtech Corp.’s upcoming earnings report date is Sep 02, 2026 which is in 80 days.
How were MicroPort CardioFlow Medtech Corp.’s earnings last quarter?
Currently, no data Available
Is MicroPort CardioFlow Medtech Corp. overvalued?
According to Wall Street analysts MicroPort CardioFlow Medtech Corp.’s price is currently Overvalued.
Does MicroPort CardioFlow Medtech Corp. pay dividends?
MicroPort CardioFlow Medtech Corp. does not currently pay dividends.
What is MicroPort CardioFlow Medtech Corp.’s EPS estimate?
MicroPort CardioFlow Medtech Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MicroPort CardioFlow Medtech Corp. have?
MicroPort CardioFlow Medtech Corp. has 1,273,311,400 shares outstanding.
What happened to MicroPort CardioFlow Medtech Corp.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of MicroPort CardioFlow Medtech Corp.?
Currently, no hedge funds are holding shares in HK:2160
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MicroPort CardioFlow Medtech Corp. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Company Description
MicroPort CardioFlow Medtech Corp.
MicroPort CardioFlow Medtech Corporation is a medical technology firm dedicated to the comprehensive research, development, and commercialization of advanced transcatheter and surgical therapies for structural heart conditions. Operating primarily within the People's Republic of China, its innovative product line includes the Vitaflow Aortic Valve System, Alwide Balloon Catheter, and Alpass Introducer Set, specifically engineered to treat aortic, mitral, tricuspid, and surgical valve disorders. The company also supplies a range of essential procedural accessories. MicroPort CardioFlow Medtech, which commenced operations in 2010, maintains its corporate headquarters in Shanghai, China.
Technical Analysis
MicroPort Scientific
―
LifeTech Scientific Corporation
―
AK Medical Holdings Ltd.
―
Venus Medtech (Hangzhou), Inc. Class H
―
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
―
Options Prices
Currently, No data available
---